Abstract:In clinical studies, the toxicity of platinum-based antitumor drugs limits their use. DNA is the most widely studied target of metal-based complexes. Thus, nuclear targeting and selective killing have become the purpose of ruthenium complex design. We synthesized a carboline derivative and its ruthenium complex, NBD and NBD-Ru, and characterized their properties. UV spectra were used to monitor their stability. Transmission electron microscopy and dynamic light scattering were used to identify the self-assembly properties. Inductively coupled plasma mass spectrometry was used to assay the distribution of the Ru complexes in cells with or without transferrin. Besides, the tumor cell killing activities with or without transferrin were detected by MTT assay. An imaging flow cytometer was applied to observe the fluorescence further to identify the cellular distribution. The effects of NBD and NBD-Ru on DNA and the cell cycle were also measured. In vivo, the antitumor and antimetastatic activities of NBD and NBD-Ru were assessed in S180 and LLC tumor-bearing mice. We found that introducing Ru improved the solubility and stability, enabling NBD-Ru to self-assemble into nanoparticles with the EPR effect. At the same time, binding affinity with transferrin increased significantly after complexation, allowing NBD-Ru could target and selectively kill tumors via Tf/TfR pathway. More interestingly, ruthenium assisted the complex in achieving nuclear penetration, which can kill tumor cells by interacting with DNA. In vivo experiments further verified our conclusion in vitro. NBD-Ru could inhibit not only the growth of a primary tumor but also lung metastasis, which was related to the killing effect of the complex on tumor cells (ki67) and inhibition of neovascularization (CD31). At the same time, the systemic toxicity of the ruthenium complex in vivo was reduced because of the targeting effect, and the biosafety was improved. In conclusion, we found that ruthenium assisted in nuclear targeting and selective killing in vitro and in vivo.

Cancer-targeting Functionalization of Selenium-Containing Ruthenium Conjugate with Tumor Microenvironment-Responsive Property to Enhance Theranostic Effects.

Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles.

A Selenium-Containing Ruthenium Complex As a Cancer Radiosensitizer, Rational Design and the Important Role of ROS-mediated Signalling

Dual Functional Half-Sandwich Ru(II) Complexes: Lysosome-Targeting Probes and Anticancer Agents

A pH-Sensitive Nanocarrier for Tumor Targeting

A Tailored Multifunctional Anticancer Nanodelivery System for Ruthenium‐Based Photosensitizers: Tumor Microenvironment Adaption and Remodeling

Drug Delivery: Cancer‐Targeted Monodisperse Mesoporous Silica Nanoparticles As Carrier of Ruthenium Polypyridyl Complexes to Enhance Theranostic Effects (adv. Funct. Mater. 19/2014)

Designing Luminescent Ruthenium Prodrug for Precise Cancer Therapy and Rapid Clinical Diagnosis.

Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Construction of functionalized ruthenium-modified selenium coated with pH-responsive silk fibroin nanomaterials enhanced anticancer efficacy in hepatocellular cancer

Selenium-containing Metallodrug Overcomes Cervical Cancer Radioresistance Through Physical-Chemical Dual Sensitization.

Lysosome-Targeted Chemotherapeutics: Half-Sandwich Ruthenium(II) Complexes That Are Selectively Toxic to Cancer Cells.

Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells.

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Ruthenium Complex-Modified Carbon Nanodots For Lysosome-Targeted One- And Two-Photon Imaging And Photodynamic Therapy

Cancer-Targeted Tri-Block Copolymer Nanoparticles As Payloads of Metal Complexes to Achieve Enhanced Cancer Theranosis

Engineering Thio-/seleno-ether Linkers into Zwitterionic Small Molecule Nano-prodrugs for Traceable Cancer Theranostics

Nucleolin-targeted selenium nanocomposites with enhanced theranostic efficacy to antagonize glioblastoma

Functionalization and Cancer-Targeting Design of Ruthenium Complexes for Precise Cancer Therapy.